Jerold S. Harmatz

Jerold S. Harmatz's AcademicInfluence.com Rankings

Jerold S. Harmatz

Medical

#2893

World Rank

#3337

Historical Rank

Pharmacology

#329

World Rank

#380

Historical Rank

medical Degrees

Jerold S. Harmatz

Philosophy

#8284

World Rank

#11632

Historical Rank

Logic

#5321

World Rank

#6712

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Jerold S. Harmatz's Degrees

PhD Pharmacology University of California, San Francisco
Doctorate Medicine University of California, San Francisco

Why Is Jerold S. Harmatz Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jerold S. Harmatz's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diazepam disposition determinants (1980) (363)
Dose‐Dependent Pharmacokinetics and Psychomotor Effects of Caffeine in Humans (1997) (333)
A New Scale for Clinical Assessment in Geriatric Populations: Sandoz Clinical Assessment – Geriatric (SCAG) * (1974) (306)
Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir (1998) (267)
A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. (1989) (266)
Sensitivity to triazolam in the elderly. (1991) (241)
Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. (1996) (241)
Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents (1996) (229)
Oxazepam kinetics: effects of age and sex. (1980) (214)
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. (2001) (205)
In vitro approaches to predicting drug interactions in vivo. (1998) (205)
Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. (2000) (196)
Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice (2003) (186)
Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. (1995) (183)
Benzodiazepines: a summary of pharmacokinetic properties. (1981) (174)
Effect of age and gender on disposition of temazepam. (1981) (170)
Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. (1994) (168)
Clinical Pharmacokinetics of Anxiolytics and Hypnotics in the Elderly (1991) (167)
Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. (1994) (166)
O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants (1999) (162)
Drug interactions with newer antidepressants: role of human cytochromes P450. (1998) (160)
Clinical Pharmacokinetics of Anxiolytics and Hypnotics in the Elderly (2012) (160)
Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4 (1998) (154)
Pharmacokinetics and Bioavailability of Intravenous, Intramuscular, and Oral Lorazepam in Humans (1979) (152)
Variability of 24‐Hour Urinary Creatinine Excretion by Normal Subjects (1976) (152)
Amitriptyline in the Treatment of Anorexia Nervosa: A Double‐Blind, Placebo‐Controlled Study (1985) (151)
Lorazepam kinetics in the elderly (1979) (150)
Inhibition of human cytochromes P450 by components of Ginkgo biloba (2004) (148)
Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo (1989) (146)
Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs (1981) (143)
Fluoxetine impairs clearance of alprazolam but not of clonazepam (1992) (135)
Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. (1999) (134)
Alterations in drug distribution and clearance due to obesity. (1981) (131)
Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors (2001) (122)
Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences (1998) (121)
Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. (2000) (120)
A double-blind placebo controlled study of desipramine in the treatment ADD: II. Serum drug levels and cardiovascular findings. (1989) (119)
Alcoholism in women. (1971) (119)
Alprazolam‐ritonavir interaction: Implications for product labeling (2000) (118)
Trazodone kinetics: Effect of age, gender, and obesity (1987) (118)
In Vitro Prediction of the Terfenadine‐Ketoconazole Pharmacokinetic Interaction (1994) (114)
Metabolism of Drugs by Cytochrome P450 3A Isoforms (1995) (114)
Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo (1998) (112)
Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine (1996) (110)
Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity. (1982) (107)
Absorption and Disposition of Chlordiazepoxide in Young and Elderly Male Volunteers (1977) (103)
In Vitro, Pharmacokinetic, and Pharmacodynamic Interactions of Ketoconazole and Midazolam in the Rat (2002) (103)
Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. (1993) (103)
Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In‐vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A (1998) (101)
Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. (1989) (99)
Implications of Altered Drug Disposition in the Elderly: Studies of Benzodiazepines (1989) (98)
Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: In vitro and clinical studies (2006) (96)
Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. (2003) (95)
N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. (1995) (95)
Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. (1999) (93)
Clinical Importance of the Interaction of Diazepam and Cimetidine (1984) (93)
Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences (1998) (93)
Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. (1987) (91)
Anorexia nervosa and affective disorders: a controlled family history study. (1984) (88)
Desmethyldiazepam kinetics in the elderly after oral prazepam (1980) (87)
Pomegranate Juice Does Not Impair Clearance of Oral or Intravenous Midazolam, a Probe for Cytochrome P450‐3A Activity: Comparison With Grapefruit Juice (2007) (85)
Pharmacokinetic Comparison of Sublingual Lorazepam with Intravenous, Intramuscular, and Oral Lorazepam (1982) (84)
Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects (1999) (84)
Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. (1996) (83)
Diazepam absorption: Effect of antacids and food (1978) (82)
Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. (2002) (82)
Comparison of Duloxetine, Escitalopram, and Sertraline Effects on Cytochrome P450 2D6 Function in Healthy Volunteers (2007) (81)
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir (2006) (80)
Plasma diazepam and desmethyldiazepam concentrations during long-term diazepam therapy. (1981) (80)
Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate (2004) (80)
Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions (1999) (79)
Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration (2014) (79)
Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Flurazepam, temazepam, and triazolam. (1989) (79)
Human cytochromes mediating N-demethylation of fluoxetine in vitro (1997) (78)
Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. (1998) (76)
Chlordiazepoxide-induced hostility in a small group setting. (1974) (74)
Absorption rate, blood concentrations, and early response to oral chlordiazepoxide. (1977) (73)
Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide (1978) (70)
Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. (1980) (70)
Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. (2015) (69)
Comparative single‐dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo (1988) (69)
Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole (1998) (68)
Long v short half-life benzodiazepines in the elderly. Kinetics and clinical effects of diazepam and oxazepam. (1983) (66)
Pharmacokinetic and Pharmacodynamic Interactions Between Zolpidem and Caffeine (2007) (65)
Absorption and disposition of ibuprofen in the elderly. (1984) (64)
Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. (1999) (63)
Relative Contribution of CYP3A to Amitriptyline Clearance in Humans: In Vitro and In Vivo Studies (2001) (62)
Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. (2009) (61)
Short‐Term Exposure to Low‐Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone (2003) (61)
Ginkgo biloba Does Not Alter Clearance of Flurbiprofen, a Cytochrome P450‐2C9 Substrate (2006) (61)
Depressive disorders in relatives of anorexia nervosa patients with and without a current episode of nonbipolar major depression. (1985) (60)
Pharmacokinetic approach to the clinical use of lidocaine intravenously. (1976) (58)
Repeated diazepam dosing in cirrhotic patients: Cumulation and sedation (1983) (56)
Inhibition of Human Cytochrome P450‐3A Isoforms by Fluoxetine and Norfluoxetine: In Vitro and In Vivo Studies (1996) (56)
Population study of triazolam pharmacokinetics. (1986) (55)
Bromazepam pharmacokinetics: Influence of age, gender, oral contraceptives, cimetidine, and propranolol (1987) (54)
Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption (1976) (54)
Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. (1996) (52)
Lorazepam and oxazepam kinetics in women on low‐dose oral contraceptives (1983) (52)
Kinetic and dynamic components of increased benzodiazepine sensitivity in aging animals. (1990) (52)
In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors (2000) (51)
Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. (1993) (48)
The Absence of an Interaction Between Warfarin and Cranberry Juice: A Randomized, Double‐Blind Trial (2009) (48)
Patterns of violent behavior among schizophrenic inpatients. (1977) (48)
The clinician and drug interactions--an update. (1996) (48)
Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. (2005) (48)
Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation. (2003) (47)
Pharmacokinetics and Pharmacodynamics of Diphenhydramine 25 mg in Young and Elderly Volunteers (1998) (46)
Fentanyl Clearance and Volume of Distribution Are Increased in Patients With Major Burns (2007) (46)
Diagnosis and lithium treatment of affective disorder in the retarded: five case studies. (1979) (44)
Sedative effects and impaired learning and recall after single oral doses of lorazepam (1986) (43)
Oxaprozin pharmacokinetics in the elderly. (1985) (43)
Langner's Psychiatric Impairment Scale: a short screening device. (1971) (43)
Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. (2003) (43)
Cytochromes in psychopharmacology. (1994) (43)
Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. (1983) (42)
Race, Gender, and Genetic Polymorphism Contribute to Variability in Acetaminophen Pharmacokinetics, Metabolism, and Protein-Adduct Concentrations in Healthy African-American and European-American Volunteers (2017) (42)
Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. (2009) (42)
Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. (1986) (41)
Dose-independent pharmacokinetics of digoxin in humans. (1978) (41)
Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. (2011) (40)
Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine. (1999) (40)
Cognitive effects of β‐adrenergic antagonists after single doses: Pharmacokinetics and pharmacodynamics of propranolol, atenolol, lorazepam, and placebo (1993) (39)
The Neuropsychiatric Effects of Aspartame in Normal Volunteers (1990) (39)
Psychotropic drugs and induced hostility. (1969) (39)
Desmethyldiazepam Pharmacokinetics: Studies Following Intravenous and Oral Desmethyldiazepam, Oral Clorazepate, and Intravenous Diazepam (1988) (39)
Factors influencing diazepam pharmacokinetics: age, sex, and liver disease. (1978) (38)
The differential effects of chlordiazepoxide and oxazepam on hostility in a small group setting. (1975) (38)
Role of NADPH-Cytochrome P450 Reductase and Cytochrome-b5/NADH-b5 Reductase in Variability of CYP3A Activity in Human Liver Microsomes (2009) (38)
Human cytochromes mediating sertraline biotransformation: seeking attribution. (1999) (38)
Prediction of treatment acceptance by child guidance clinic applicants: an easily applied instrument. (1972) (37)
Psychotropic drug prescribing in the United States: extent, costs, and expenditures. (2011) (36)
Heterogeneity in anorexia nervosa (1986) (36)
The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. (1991) (36)
Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. (2013) (35)
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection (2018) (35)
Effect of zolpidem on human Cytochrome P450 activity, and on transport mediated by P‐glycoprotein (2002) (34)
Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder. (1993) (34)
Apparent mechanism‐based inhibition of human CYP3A in‐vitro by lopinavir (2003) (34)
Effect of Age on in Vitro Triazolam Biotransformation in Male Human Liver Microsomes (2004) (33)
Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. (1989) (33)
Adverse reactions to triazolam, flurazepam, and placebo in controlled clinical trials. (1984) (33)
Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro (2010) (33)
Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test. (2005) (32)
Interaction of Diazepam With Famotidine and Cimetidine, Two H2‐Receptor Antagonists (1986) (32)
Single‐Dose Pharmacokinetics and Pharmacodynamics of Alprazolam in Elderly and Young Subjects (1998) (31)
Absence of Interaction of Cimetidine and Ranitidine with Intravenous and Oral Midazolam (1986) (30)
Zolpidem and Gender: Are Women Really At Risk? (2019) (30)
A simplex procedure for fitting nonlinear pharmacokinetic models. (1987) (30)
Update on Psychotropic Drug Prescribing in the United States: 2014-2015. (2017) (29)
Urinary mhpg in anorexia nervosa patients with and without a concomitant major depressive disorder. (1984) (29)
Pomegranate Juice and Pomegranate Extract Do Not Impair Oral Clearance of Flurbiprofen in Human Volunteers: Divergence From In Vitro Results (2012) (28)
Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes. (2000) (28)
Antipyrine absorption and disposition in the elderly. (1988) (28)
Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms (1997) (28)
Pharmacokinetic properties of benzodiazepine hypnotics. (1983) (27)
Pharmacokinetics and bioavailability of digoxin capsules, solution and tablets after single and multiple doses. (1978) (27)
Kinetics and EEG Effects of Midazolam during and after 1‐Minute, 1‐Hour, and 3‐Hour Intravenous Infusions (2004) (25)
Platelet MAO activity in anorexia nervosa patients with and without a major depressive disorder. (1984) (25)
Interaction of triazolam and ketoconazole (1995) (24)
Gas chromatographic analysis of alprazolam in plasma: replicability, stability and specificity. (1990) (24)
Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen (2015) (24)
Inhibition of Triazolam Hydroxylation by Ketoconazole, Itraconazole, Hydroxyitraconazole and Fluconazole In‐vitro (1998) (24)
Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate (1979) (24)
Noninteraction of temazepam and cimetidine. (1984) (23)
Kinetic and dynamic interaction of brotizolam and ethanol. (1986) (23)
Triazolam Kinetics: Interaction with Cimetidine, Propranolol, and the Combination (1988) (23)
Validity of Self‐Reports of Caffeine Use (1991) (22)
Zolpidem Pharmacokinetic Properties in Young Females: Influence of Smoking and Oral Contraceptive Use (2002) (21)
Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects (1998) (21)
Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. (1990) (21)
Clearance of the Antihistamine Doxylamine (1989) (19)
Pharmacokinetics of intravenous caffeine: comparison of high-performance liquid chromatographic and gas chromatographic methods. (1987) (19)
The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state (1992) (19)
Plasma concentrations and clinical effects after single oral doses of prazepam, clorazepate, and diazepam. (1984) (19)
Sandoz Clinical Assessment-Geriatric (SCAG). (1988) (19)
Characterization of cognitive dysfunction in Sjögren’s syndrome patients (2014) (19)
Effects of chlordiazepoxide and oxazepam administration on verbal hostility. (1977) (19)
Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety (2018) (18)
Molecular and Pharmacokinetic Evaluation of Rat Hepatic and Gastrointestinal Cytochrome P450 Induction by Tamoxifen (2001) (18)
Psychopharmacologic Investigations in Healthy Elderly Volunteers: MMPI Depression Scale † (1975) (18)
The therapist variable. (1971) (18)
MMPI profiles in anorexia nervosa patients with and without major depression (1986) (18)
Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam (1983) (18)
Sex differences in diazepam protein binding in patients with renal insufficiency. (1978) (18)
Benzodiazepines: Safety and toxicity. (1975) (16)
Clearance of the antihistamine doxylamine. Reduced in elderly men but not in elderly women. (1989) (16)
The effect of age on sildenafil biotransformation in rat and mouse liver microsomes. (2003) (16)
Kinetic-dynamic modeling in clinical psychopharmacology. (1993) (16)
Bioinequivalence of a generic brand of diazepam. (1989) (15)
Mechanism-based inhibition of human Cytochrome P450-3A activity by grapefruit hybrids having low furanocoumarin content (2012) (15)
Effect of lipophilicity on drug distribution and elimination: Influence of obesity (2021) (15)
Lidocaine plasma concentrations following administration of intraoral lidocaine solution. (1985) (15)
Correlates of outcome following acute glutethimide overdosage. (1979) (15)
Studies With Stable Isotopes III: Pharmacokinetics of Tracer Doses of Drug (1985) (15)
Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. (1990) (15)
High frequency of HLA-Bw16 in patients with anorexia nervosa. (1984) (15)
Effect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers. (2013) (15)
Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. (2000) (15)
Clonazepam Pharmacokinetics: Comparison of Subcutaneous Microsphere Injection With Multiple‐Dose Oral Administration (2005) (14)
Single‐Dose Kinetics of Prazepam, a Precursor of Desmethyldiazepam (1979) (14)
Absolute bioavailability of imipramine: Influence of food (2004) (14)
A randomized, double-blind trial of the interaction between cranberry juice and warfarin (2008) (14)
Obesity effects on nitrazepam disposition. (1986) (14)
Kinetics and dynamics of single doses of oxazepam in the elderly: implications of absorption rate. (1986) (14)
Changes in salivary antipyrine pharmacokinetics during adolescence, correlated with age, hormonal levels and Tanner stage. (1991) (13)
HLA haplotype A26–B38 in affective disorders: Lack of association (1987) (13)
Single- and multiple-dose kinetics of oral lorazepam in humans: The predictability of accumulation (1979) (12)
Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine. (1998) (12)
Pharmacokinetics of Zolpidem from Sublingual Zolpidem Tartrate Tablets In Healthy Elderly Versus Non-Elderly Subjects (2014) (12)
Persistence of a Posaconazole‐Mediated Drug‐Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety (2018) (11)
Alprazolam hydroxylation by mouse liver microsomes in vitro: the effect of age and phenobarbital induction. (1997) (11)
Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate (2004) (10)
Marihuana users and nonusers. Personality test differences. (1972) (10)
Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety (2018) (10)
Simplified approaches to the determination of antipyrine pharmacokinetic parameters. (1988) (10)
Characterological anxiety levels and premenstrual libido changes. (1968) (10)
Long v short half-life benzodiazepines in the elderly???kinetics and clinical effects of diazepam and oxazepam (1983) (10)
Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets (2013) (10)
Corticosteroid responses to milieu therapy of chronic schizophrenics. (1966) (9)
Pharmacokinetics of chlordiazepoxide and metabolites following single and multiple oral doses. (1978) (9)
Response of the elderly to psychotrophic drugs: predictable or idiosyncratic? (1975) (9)
Towards an Observational Structure for Rating Dysfunction and Pathology in Ambulatory Geriatrics1 (1979) (8)
Serum digoxin concentrations and subjective manifestations of toxicity. (1980) (8)
Nefazodone in vitro: Metabolic conversions, and inhibition of P450‐3A isoforms (1996) (8)
Emergency room study of sedative-hypnotic overdosage: a study of the issues (1982) (7)
Body Size Changes Among National Collegiate Athletic Association New England Division III Football Players, 1956-2014: Comparison With Age-Matched Population Controls. (2016) (7)
Falling off the straight line: some hazards of correlation and regression. (1992) (7)
Absolute bioavailability of imipramine: Influence of food (2004) (7)
Disposition of clotiazepam: Influence of age, sex, oral contraceptives, cimetidine, isoniazid and ethanol (2004) (7)
Acetaminophen pharmacokinetics in women receiving conjugated estrogen (2004) (7)
Sensitivity to Triazolam in the Elderly (1992) (6)
Benzodiazepine response and receptor binding after chronic ethanol ingestion in a mouse model. (1991) (6)
Stress and bronchitis. (1968) (5)
Population Pharmacokinetics of Methylphenidate (1999) (5)
Tybamate: an examination of its actions in "high" and "low" anxious normals. (1969) (4)
Arithmetic Versus Harmonic Mean Values of Elimination Half‐Life: A Study of Triazolam (1989) (4)
Vitamin C prophylaxis and some problems of statistical inference. (1974) (4)
Diazepam in the Elderly: Looking Back, Ahead, and at the Evidence. (2020) (4)
Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine (2004) (4)
Clinical implications of serum digoxin concentrations (1981) (3)
Factors influencing blood concentrations of chlordiazepoxide: A use of multiple regression analysis (1977) (3)
Is oxazepam associated with hostility? (1975) (3)
A Randomized, Double-Blind Trial of the Interaction between Cranberry Juice and Warfarin. (2006) (3)
Self-rated sedation and plasma concentrations of desmethyldiazepam following single doses of clorazepate (2004) (3)
Pharmacokinetic profile of SKP‐1041, a modified release formulation of zaleplon (2011) (3)
Molindone: a pilot evaluation during the premenstruum. (1975) (3)
38 PHARMACOKINETICS , PHARMACODYNAMICS , AND DRUG DISPOSITION (2002) (3)
Slow Accumulation and Elimination of Diazepam and Its Active Metabolite With Extended Treatment in the Elderly (2020) (2)
An evaluation of isoquinazepon (SAH-1123). (1967) (2)
Mechanism of dasabuvir inhibition of acetaminophen glucuronidation. (2021) (2)
Single versus repeated dosage of the minor tranquilizer chlordiazepoxide (Librium). (1972) (2)
Regression and Correlation (2015) (2)
Effect of an Herbal Extract Containing Curcumin and Piperine on Midazolam , Flurbiprofen , and Acetaminophen Pharmacokinetics in Healthy Volunteers (2012) (2)
Bioequivalence studies in the elderly: a pilot study of two oxazepam dosage forms. (1987) (2)
Resveratrol glucuronidation in vitro: potential implications of inhibition by probenecid (2018) (2)
Drug Disposition in Subjects With Obesity: The Research Work of Darrell R. Abernethy (2022) (2)
Effect of blood collection tubes on antidepressant concentrations. (1987) (2)
An irreverent look at the t test. (2009) (1)
Alprazolam, panic disorder, and the new 2 mg tablet. (1991) (1)
Ritonavir impairs clearance and enhances toxicity of trazodone (2003) (1)
Contents Vol. 63, 2001 (2001) (1)
Diurnal Variation of Sodium and Water Metabolism Among Patients with Psychosis, Intermittent Hyponatremia, and Polydipsia (PIP Syndrome) (1987) (1)
Clinically unimportant pharmacokinetic drug interaction between fluvoxamine and single doses of caffeine (2005) (1)
An investigation of the stimulating and mood-elevating properties of pipradol HCl administered to clinically normal volunteers. (1968) (1)
The UGT2B15*2 polymorphism is a major determinant of oxazepam clearance in human volunteers. (2009) (0)
Comparative effects of single and repeat dose administration of antianxiety agents. (1971) (0)
Subject Index Vol. 63, 2001 (2001) (0)
Menarcheal Age and Personality: The Choice of a Statistical Test of Relationship (1974) (0)
Planning Pharmaceutical Clinical Trials. Basic Statistical Principles (1995) (0)
Steady-state plasma desmethyldiazepam during long-term clorazepate use: effect of antacids (1982) (0)
Tentative Approaches to Testing Elderly Volunteers in a Drug Trial. (1976) (0)
Thinking while balancing: what to do about replacing dropouts. (1994) (0)
Twenty-five years of recurring methods questions in a clinical psychopharmacology laboratory (1992) (0)
Recovery of CYP3A function following single doses of grapefruit juice (2003) (0)
Letter: Correlation of human menstruation and lunar phase. (1975) (0)
Cytochrome P 450-3 A Activity : Comparison With Grapefruit Juice Pomegranate Juice Does Not Impair Clearance of Oral or Intravenous Midazolam , a Probe for (2007) (0)
Chlordiazepoxide and Hostility (2015) (0)
with the highly significant reduction in clearance of the oxidized benzodiazepine diazepam. (1982) (0)
Kinetic anddynamic interaction ofbrotizolam andethanol (1986) (0)
The effect of age on triazolam hydroxylation in human liver microsomes from males (2003) (0)
CLINICAL PHARMACOKINETICS OF LORAZEPAM 4, LONG-TERM ORAL ADMINISTRATION (1978) (0)
W-D-017 PHARMACOKINETIC PROFILE OF A MODIFIED RELEASE FORMULATION OF ZALEPLON (SKP-1041) 10.0 MG, 15.0 MG, AND 20.0 MG IN ADULTSWITH PRIMARY SLEEP MAINTENANCE INSOMNIA (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jerold S. Harmatz?

Jerold S. Harmatz is affiliated with the following schools:

Tufts University

Jerold S. Harmatz's Academic­Influence.com Rankings

Jerold S. Harmatz's Degrees

Why Is Jerold S. Harmatz Influential?

Jerold S. Harmatz's Published Works

Published Works

What Schools Are Affiliated With Jerold S. Harmatz?

Jerold S. Harmatz's AcademicInfluence.com Rankings